- In March 2025, Pfizer Inc. announced promising Phase III clinical trial results for its next-generation anti-convulsant, PF-327201, developed for managing post-traumatic seizures in moderate to severe TBI patients. The trial demonstrated a significant reduction in early seizure incidence, with fewer cognitive side effects compared to traditional therapies such as phenytoin
- In December 2024, UCB S.A. launched an expanded access program in the U.S. for Briviact (brivaracetam) in acute care TBI settings. The program aims to support hospitals treating high-risk neurotrauma patients, following new clinical guidelines advocating the use of levetiracetam-based therapies due to their favourable safety profile
- In November 2024, Eisai Co., Ltd. collaborated with the Japanese Brain Trauma Foundation to fund AI-based research into seizure prediction and personalized anti-convulsant dosing for ICU patients with traumatic brain injury. The project integrates EEG and neuroimaging data to optimize real-time treatment
- In September 2024, Teva Pharmaceuticals introduced a new injectable formulation of valproate sodium specifically designed for rapid administration in emergency neurocritical care settings. This innovation addresses the need for faster seizure control during the golden hour of TBI intervention
